Hair Removal
evidence map home
hair-removal/_summary

Hair Removal — Evidence Map

Status: draft complete (compiled 2026-04-18)

Scope: permanent hair reduction/removal methods (laser by wavelength; electrolysis by current type — galvanic, thermolysis, blend, multi-probe; emerging modalities — microwave miraSmooth, nanoparticle-assisted, PDT, IPL+RF hybrids) and temporary methods (shaving, waxing, sugaring, threading, depilatory creams, tweezing, epilators), with topical/systemic pharmacology for unwanted hair (eflornithine, spironolactone, cyproterone, 5-ARIs, GnRH agonists, COCs) and population-specific considerations (Fitzpatrick V-VI, transgender peri-operative, PCOS/hirsutism, sensitive anatomy, PFB, AKN, hidradenitis).

Confidence tiers used throughout: C1 = Phase 3 / multiple meta-analyses converging; C2 = multiple RCTs or strong meta-analyses with heterogeneity; C3 = small RCTs, Phase 2, strong open-label series; C4 = case series / anecdote / unregulated; C5 = hype or disproven.

Companion files in this folder: laser.md (wavelength/Fitzpatrick deep dive), electrolysis.md (galvanic/thermolysis/blend/multi-probe deep dive), temporary-and-topicals.md (shave/wax/sugar/thread/depilatory + eflornithine + systemic pharmacology + home devices), emerging-and-populations.md (PDT, miraSmooth, nanoparticle, anaesthetics, populations, PFB/HS).

Recursive deepdive directories (added 2026-04-20 — these expand each tier into method-level, physics-level, and population-level detail):

Key takeaways

  1. The two established permanent modalities are laser (permanent reduction) and electrolysis (permanent removal). FDA permits the "removal" wording only for electrolysis — no laser or IPL device is cleared for it. This is a regulatory distinction that partly tracks clinical reality: electrolysis is per-follicle definitive when technique is correct, laser is per-course density reduction that tends to plateau around 70-90%.
  2. Laser type matches skin type, not marketing: alexandrite 755 nm for Fitzpatrick I-III, diode 810 nm for III-IV, Nd:YAG 1064 nm for IV-VI. Alexandrite on dark skin is the dominant preventable-harm pattern (burns, dyspigmentation, paradoxical hypertrichosis). IPL is a broad-spectrum compromise — usually less effective than a matched laser per session.
  3. Laser fails on blonde, red, grey, white hair. Electrolysis is the only reliable permanent method for these because it does not depend on melanin as a chromophore. Gold/silver nanoparticle-assisted photothermolysis and PDT have been tried to work around this but are not clinically established (Sebacia wound down in 2020-21; PDT remains experimental).
  4. Electrolysis has three modalities with meaningfully different physics: galvanic (DC chemistry, 1875 Michel), thermolysis / shortwave diathermy (13.56 MHz RF heat, 1924 Bordier), and blend (both at once, 1945 Hinkel + St. Pierre). Per-insertion regrowth: flash thermolysis ~30-50%, galvanic ~15-25%, blend ~10-20%. Blend is the US/Canadian standard for coarse / curly / deep follicles.
  5. Multi-probe galvanic (10-32 needles in parallel) increases throughput but is skill-sensitive and has a higher scarring signal when throughput is prioritised over per-needle dose control.
  6. The only modern comparative head-to-head on a clinically meaningful endpoint is the 2022 pre-vaginoplasty comparison (Salibian / Zhang, PMC9537259): electrolysis averaged 24.3 sessions / 48.1 h / $5,161 / pain 6.9 vs laser 8.1 sessions / 1.9 h / $962 / pain 4.4 to reach "<5 hairs regrowth / 2 months." Both reached the endpoint; laser was far more efficient when hair colour allowed it.
  7. Paradoxical hypertrichosis (0.6-10% incidence; mostly face/neck in women with Mediterranean / Middle Eastern / South Asian ancestry; alexandrite + IPL most implicated): likely subthermal stimulation of dormant follicles. Management = switch to Nd:YAG or SHR diode at full fluence; electrolysis for residual induced hairs. Does not occur with electrolysis.
  8. Eflornithine HCl 13.9% cream (Vaniqa) is the only FDA-approved topical that slows unwanted facial-hair growth. Mechanism = irreversible ornithine-decarboxylase inhibition blocking polyamine synthesis. ~32-38% marked-improvement vs ~8-9% vehicle at 24 weeks. Does not remove hair; effect plateaus and reverts in ~8 weeks after stopping. Adjunct to laser: additive (Hamzavi 2007).
  9. Systemic pharmacology for hirsutism (Endocrine Society 2018 guideline): combined OCP first-line; add spironolactone 100 mg/day (or cyproterone where available); 5-ARIs second-line; GnRH agonists reserved for severe cases. All slow progression; none eliminate established terminal hair cosmetically — laser/electrolysis still needed for visible clearance.
  10. Cyproterone's dose-dependent meningioma signal (Weill 2021 BMJ n≈253,000 French women; ≥3 g cumulative ~7×, ≥60 g ~20×) shifted global practice toward lower doses. Low-dose (≤10 mg/day) long-term trans-HRT use is under-characterised.
  11. Shaving does not thicken hair (Lynfield 1970 J Invest Dermatol; Saitoh 1967; Trotter 1928). The stubble illusion is cut cross-section, not biology.
  12. Home IPL / diode devices (Philips Lumea, Braun, Tria 4X, Ulike, Nood, Silk'n, JOVS) deliver 3-10 J/cm² vs clinic 15-30+ J/cm². Real but modest: 30-60% reduction at end of regimen, much of it regrows within 12 months post-stopping. Safe at label fluences in Fitz I-IV; skin-tone sensors lock out darker skin.
  13. For transgender pre-operative genital clearance (vaginoplasty, phalloplasty): WPATH SOC-8 endorses hair removal as medically necessary. US insurance coverage is patchwork but expanding; pre-surgical genital clearance is the most consistently approved indication. Practical planning: 9-15 months lead time, 1.9-48 h total depending on hair colour and modality.
  14. Do not laser inside the orbital rim. Iritis, iris atrophy, uveitis, posterior synechiae, pupillary distortion are all documented after periocular alexandrite or diode, including with external shields. Wavelength-specific intraocular shields (Oculoplastik, Cox II) are mandatory for brows-outside-rim. (Electrolysis is the only reasonable choice for any hair inside the orbital rim.)

One-page modality comparison

Method Permanence Hair-colour range Skin-type range Speed Pain Cost (full course) Best-use
Shaving Temporary (days) Any Any Fast None $5-50/yr Daily maintenance
Depilatory cream Temporary (days-wk) Any Sensitivity-limited Fast Mild $5-20/mo Below-surface cut useful for PFB; skin-test first
Waxing / sugaring Temporary (2-6 wk) Any Any, not on retinoid/isotretinoin users Moderate 5-7/10 $300-900/yr/region Bulk areas when 2-4 wk regrowth acceptable
Threading Temporary (2-4 wk) Any Any Moderate 4-6/10 $10-25/session Brows, upper lip
Epilator Temporary (2-4 wk) Any Any Moderate 5-7/10 $50-150 device Home maintenance, body
Home IPL / diode Reduction (fades) Dark on light/medium only Fitz I-IV (lockouts) Weekly protocol 2-5/10 $200-500 device Dark hair on light skin, maintenance
Clinic laser (alex 755) Permanent reduction (65-85%) Dark, terminal Fitz I-III (IV with caution) Fast per area 4-6/10 $1-3k face, $3-8k body Fitz I-III dark coarse hair
Clinic laser (diode 810) Permanent reduction Dark Fitz I-IV, V with SHR Fast 3-5/10 Same Versatile; SHR variants extend to darker
Clinic laser (Nd:YAG 1064) Permanent reduction Dark Fitz IV-VI gold standard Moderate 5-7/10 Same Dark skin, PFB, HS, AKN
Microwave (miraSmooth) Permanent reduction (~70%) Any (melanin-independent) Any Slow; axilla only 3-5/10 (under local) ~$1-3k axillae Axillae only per label
Electrolysis (thermolysis) Permanent per-follicle Any Any Slow (fast per insertion, many needed) 3-6/10 $3-15k+ face Speed-optimised sessions, disciplined practitioner
Electrolysis (galvanic) Permanent per-follicle Any Any Very slow 2-5/10 Higher Hormone-resistant, distorted follicles, grey/white/blonde
Electrolysis (blend) Permanent per-follicle Any Any Slow-moderate 4-7/10 $3-15k+ face Coarse+curly+deep follicle standard
Eflornithine (Vaniqa) Slows growth only Any Any N/A None $50-150/mo ongoing Adjunct to laser, facial only
Spironolactone Slows androgen-driven Any Any N/A (oral) None $5-20/mo PCOS, trans HRT; ~15-40% F-G reduction
COC + spironolactone Slows androgen-driven Any Any N/A (oral) None $15-40/mo Endocrine Society first-line combo hirsutism

Laser hair removal — detail summary

See laser.md for full notes.

Mechanism

Selective photothermolysis (Anderson & Parrish 1983, Science 220:524-527): pulsed light + melanin chromophore in the hair shaft → thermal destruction of bulge stem cells and dermal papilla. Pulse tuned between epidermal TRT (~3-10 ms) and follicular TRT (~40-100 ms). Longer "thermal damage time" pulses (170-1000 ms, Altshuler & Anderson 2001) allow heat to diffuse from shaft to bulge stem cells, enabling follicular destruction even when direct absorption drops off.

Wavelengths

Wavelength Depth Best Fitzpatrick Notes
Ruby 694 nm Shallow — Obsolete; too hypopigmentogenic
Alexandrite 755 nm Shallow-moderate I-III Gold-standard light skin; highest paradoxical hypertrichosis signal
Diode 800-810 nm Moderate I-IV (SHR to V) Versatile; LightSheer DESIRE, Candela GentleLASE
Nd:YAG 1064 nm Deep IV-VI Low melanin absorption at surface; safest for dark skin; preferred for PFB, HS
Tri-wavelength diode (755+810+1064) Stacked All, marketed Alma Soprano Titanium / ICE; independent head-to-head evidence thin
IPL broadband 500-1200 nm Variable I-III primarily Flashlamp, not a laser; larger spot, lower per-pulse efficiency

Fitzpatrick × wavelength rules

Protocol

Complications

Home devices

FDA-cleared for "permanent hair reduction" under 510(k). IPL-based (Philips Lumea, Braun, Ulike, Nood, Silk'n, JOVS) vs true diode (Tria 4X). 3-10 J/cm² vs clinic 15-30+. 30-60% reduction at regimen end (Alster 2009 Silk'n, Trelles 2012 Lumea, Mulholland 2009 Tria). Most effect regrows within 12 mo post-stopping. Skin-tone sensor lockouts on darker skin. Ocular hazard near eyes.

Electrolysis — detail summary

See electrolysis.md for full notes.

The three modalities

Modality Current Mechanism Time/follicle Regrowth Pain
Galvanic DC, 0-3 mA Faraday-law chemistry: NaCl + H₂O → NaOH at cathode, saponifies follicle 20 s - 2 min 15-25% 2-5/10 dull
Thermolysis / shortwave diathermy / RF 13.56 MHz AC, 0-8 W Water-dipole oscillation → resistive heat → coagulation at 48-50 °C 0.01-1 s (flash) 30-50% 3-6/10 sharp
Blend DC + RF simultaneously Sub-galvanic-threshold DC accelerated by RF heat (Arrhenius ~2× per 10 °C) 2-10 s 10-20% 4-7/10 mixed
Multi-probe galvanic DC, parallel needles Parallel galvanic, 10-32 needles 3-20 s effective 15-25% 3-5/10

Key facts

Session cadence

Trans-specific clearance

Temporary methods — short summary

See temporary-and-topicals.md for full notes.

Pharmacology — short summary

See temporary-and-topicals.md for full notes.

Agent Mechanism Endpoint Notes
Eflornithine 13.9% cream (Vaniqa) Irreversible ODC inhibition → polyamine depletion → slowed shaft proliferation ~32-38% "marked improvement" at 24 wk vs ~9% vehicle (Shapiro 2001; FDA label 2000) Slows only; reverts in ~8 wk after stopping. Additive to laser (Hamzavi 2007).
Spironolactone 50-200 mg/day Aldosterone antagonism + AR antagonism F-G reduction 15-40% at 6-12 mo; Cochrane Brown 2016 Standard trans-feminine antiandrogen in US. Hyperkalaemia risk; routine K monitoring in young women of low yield (Plovanich 2015). Pregnancy: contraindicated.
Cyproterone acetate 10-100 mg/day Steroidal AR antagonist, progestogenic, gonadotropin-suppressive Effective for hirsutism and trans-feminine HRT ex-US Meningioma risk dose-dependent: Weill 2021 BMJ ≥3 g cumulative ~7×, ≥60 g ~20×. Low-dose long-term signal under-characterised. VTE risk (Diane-35 history). Hepatotoxicity at high doses.
Finasteride 2.5-5 mg/day (oral, off-label hirsutism) 5α-reductase type 2 inhibition F-G reduction modest Pregnancy category X. Second-line after spiro/CPA + COC.
Dutasteride 0.5 mg/day Dual 5-AR type 1+2 F-G reduction ~6 pts at 6 mo vs finasteride ~4 (Lumachi 2003) Not FDA-approved for hirsutism.
GnRH agonists (leuprolide etc.) LH/FSH suppression → ovarian androgen ↓ Effective but menopausal effects Bone-density loss, hot flashes; reserved for severe.
COCs (drospirenone, cyproterone, dienogest) Ovarian androgen ↓ + SHBG ↑ F-G ~15-25% at 6-12 mo Endocrine Society first-line; combined with spiro for moderate-severe hirsutism. Diane-35 VTE risk elevated.

Hirsutism workup (F-G >8, East Asian >6): total and free testosterone, DHEAS, 17-OHP, prolactin, TSH; ACTH stim for NCCAH if 17-OHP borderline; dexamethasone suppression if Cushing features; imaging if rapid virilisation or total T >150 ng/dL.

Emerging and experimental

See emerging-and-populations.md for full notes.

Population-specific

See emerging-and-populations.md for full notes.

Fitzpatrick IV-VI / skin of colour

Nd:YAG 1064 is the standard of care. Starting parameters Fitz V-VI: 20-40 ms pulse, 10-12 mm spot, 24-40 J/cm², robust contact cooling / cryogen. Alex 755 / diode 810 burn Fitz V-VI unless fluence is dropped substantially. PIH is commonest complication: <2% with calibrated Nd:YAG, higher with shorter wavelengths.

Transgender women / transfeminine

PCOS / hirsutism

Endocrine Society 2018 guideline: COC first-line; add spironolactone 100 mg/day (or CPA ex-US) for moderate-severe; 5-ARIs second-line; eflornithine for face; GnRH agonist reserved. Laser + medical > either alone. 6-9+ months for full effect. Metformin no better than placebo for hirsutism score.

Sensitive anatomy

Pseudofolliculitis barbae (PFB) and acne keloidalis nuchae (AKN)

Hidradenitis suppurativa (HS)

Nd:YAG 1064 reduces disease severity in Hurley I-II (Mahmoud 2010 JAAD; Xu 2011 JAMA Dermatol; 2024 alexandrite RCT; 2025 systematic review). C2 adjunct.

Anaesthetics and aftercare

See emerging-and-populations.md for the full anaesthetic table.

Agent Composition Onset OTC/Rx Key risks
EMLA lido 2.5% + prilo 2.5% 45-60 min occluded OTC US methaemoglobinaemia (prilocaine → o-toluidine); infants/G6PD
LMX-4/5 liposomal lido 4-5% 30 min, no occlusion OTC prilocaine-free; still CNS/CV if abused
Ametop tetracaine 4% gel 30-45 min UK higher local erythema than EMLA
BLT benzo 20 + lido 6 + tet 4 30-60 min Rx compounded benzocaine methaemoglobinaemia; corneal injury if near eye
Pliaglis lido 7 + tet 7 peel 20-30 min Rx erythema 47%, discolouration 16%

See also: research/hair-removal-pain-reduction/ for the full pain-control deep dive covering topicals, nerve blocks, nitrous oxide, behavioural adjuncts, modality-specific pain ranking, and fatal-case safety history.

Documented deaths from compounded high-concentration lidocaine under occlusion prior to laser hair removal: Kristie Rae Kubicek 2004, Shiri Berg 2005 (NC). FDA 2007 Public Health Advisory specifically targets compounded high-concentration topicals. Lidocaine BSA rule: ≤4.5 mg/kg plain, ≤7 mg/kg with epi.

Cooling: sapphire contact, Candela DCD cryogen spray, Zimmer Cryo 6 forced cold air, ice. Integral to modern laser safety at higher fluences.

HSV prophylaxis: valacyclovir 500 mg BID × 10-14 d starting day before, for known history + perioral/genital work. 100% prevention in laser-resurfacing RCTs.

Cost summary (US, 2025-26)

Method Unit cost Course/annual
Shaving $5-50 $5-50/yr
Depilatory cream $5-10/tube $5-20/mo
Waxing salon $30-80/session $300-900/yr/region
Sugaring salon same + $10-20 similar
Threading salon $10-25/session $60-200/yr face
Home IPL/diode device $200-500 one-time maintenance indefinite
Clinic laser face+neck (6-8 sessions) $40-70/session upper lip $1,500-3,500 course
Clinic laser full body (6-8) — $3,000-8,000 course
Electrolysis face $50-150/hr, $120-200/hr metro $3,000-15,000+ full face; $10,000-40,000 trans full clearance
Eflornithine 13.9% cream $50-150/30 g ongoing
Spironolactone $5-20/mo generic ongoing
Cyproterone (ex-US) €10-30/mo ongoing

Flagged unknowns

Evidence tier map

Topic Tier
SPTL mechanism, FDA classification, 21 CFR 878.5350 C1
Nd:YAG for Fitz IV-VI, PFB, AKN, HS C1-C2
Alex/diode for Fitz I-III C1
Eflornithine efficacy, FDA label C1
Spiro/CPA/COC for hirsutism C1
Weill 2021 cyproterone meningioma signal C1
Lynfield 1970 shaving-doesn't-thicken C1
Salibian 2022 vaginoplasty laser vs electrolysis C2
Richards & Meharg 1995 electrolysis observations C3
Flash thermolysis regrowth 30-50% C3
Blend per-insertion efficacy C3
Multi-probe galvanic scarring signal C4
miraSmooth axillary C3
PDT for hair removal C4
Sebacia gold-nanoparticle hair C4, defunct
Electric tweezers permanence C5 disproven
"Hair-inhibitor" cosmetic lotions C5
AMA recognition date of electrolysis Soft-sourced (CPT 17380 exists)
Kobayashi 1985 per-insertion destruction numbers C4 (verification gap)

Key sources

Laser

Electrolysis

Temporary & pharmacology

Emerging & populations

Community-knowledge layer

New companion files: community-trans.md, community-practitioner-selection.md, community-sessions.md, community-cost-insurance.md, community-pitfalls.md

The community layer now does a different job from the clinical chapters. Instead of repeating the wavelength matrix or the electrolysis modality overview, it explains what the literature tends to under-describe: how trans hair-removal culture accumulated across Susan's Place, Hairtell, and later Reddit; how a real transfeminine course usually unfolds from first consult to maintenance; which currently verifiable clinics are repeatedly named in trans circles; and why the practical bottlenecks are often scheduling, insurance paperwork, or emotional endurance rather than pure device efficacy. That material now lives mainly in community-trans.md, which should be read as the lived-experience companion to the main laser and electrolysis chapters rather than as an alternative evidence base.

Provider choice, session management, and failure recognition each now have their own chapters because the communities know different things in each domain. community-practitioner-selection.md is about clinic archetypes, device inventory, consult language, and why chain branding predicts less than whether the operator can explain wavelength, cooling, cadence, and fallback logic. community-sessions.md is about cadence, shedding, comfort stacks, first clearance, and the practical signs that a course is working. community-pitfalls.md isolates the repeated failure modes: contract traps, tanning into treatment, paradoxical hypertrichosis denied as "normal," electrolysis that never clears, and incomplete pre-vaginoplasty clearance with postoperative consequences.

community-cost-insurance.md is the administrative counterpart to all of this. It now focuses on verified 2026 pricing, current payer behavior, the documentation structure that successful prior authorizations usually require, and the distinction between states with clean public Medicaid pathways, such as Washington and Massachusetts, and states where favorable rhetoric still does not translate into a simple face/body hair-removal workflow. Taken together, the community files now function as a guide to the operational realities around the evidence map rather than a duplicate summary of it.

Compiled from research/hair-removal/. Sources inline. AI-compiled research; fact-checked but not personally verified.
ai gen